Polymers

• US 10,092,663 B2
• Filed: 04/03/2015
• Issued: 10/09/2018
• Est. Priority Date: 04/29/2014
• Status: Active Grant

• Current Assignee: Terumo Corporation
• Original Assignee: Terumo Corporation
• Inventors: Constant, Michael, Cruise, Gregory M., Chen, Samuel
• Primary Examiner(s): ROGERS, JAMES WILLIAM
• Application Number:
  US14/678,468
• Publication Number:
  US 20150306255A1
• Time in Patent Office: 1,285 Days
• Field of Search: None
• CPC Class Codes: A61K 49/0404 containing barium sulfate
• CPC Class Codes: A61K 49/0409 Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: D01D 5/00 Formation of filaments, threads, or the like
• CPC Class Codes: D01D 5/38 Formation of filaments, threads, or the like during polymerisation
• CPC Class Codes: D01F 1/10 Other agents for modifying properties
• CPC Class Codes: D01F 6/28 from copolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
• CPC Class Codes: D10B 2509/00 Medical; Hygiene

Abstract

Polymers are described herein comprising: a reaction product of a prepolymer solution including at least one macromer, at least one flexomer, and at least one visualization agent. Methods of making and using these polymers are also described.

Claims

1. A polymer filament comprising:

a pentaerythritol and polyethylene glycol copolymer; and

between about 20% w/w and about 70% w/w barium sulfate;

wherein the co-polymer is a reaction product of a prepolymer solution including at least one pentaerythritol macromer and at least one polyethylene glycol flexomer;

wherein the at least one pentaerythritol macromer has a molecular weight between about 700 g/mole to about 1,000 g/mole; and

wherein the at least one polyethylene glycol flexomer has a molecular weight between about 8,000 g/mole to about 12,000 g/mole.

2. The polymer filament of claim 1, wherein the at least one pentaerythritol macromer is a multifunctional, ethynically unsaturated, shapeable macromer.

3. The polymer filament of claim 1, wherein the at least one pentaerythritol macromer is ethoxylated pentaerythritol, ethoxylated pentaerythritol tetra-acrylamide, or combinations thereof.

4. The polymer filament of claim 1, wherein the at least one pentaerythritol macromer is ethoxylated pentaerythritol.

5. The polymer filament of claim 1, wherein the at least one pentaerythritol macromer has a concentration from about 5% to about 50% w/w.

6. The polymer filament of claim 1, wherein the at least one polyethylene glycol flexomer is a difunctional, ethylenically unsaturated polyethylene glycol flexomer.

7. The polymer filament of claim 1, wherein the at least one polyethylene glycol flexomer has a concentration of between about 0.1% w/w and about 1% w/w of the prepolymer solution.

8. The polymer filament of claim 1, wherein the polymer filament does not include metallic support members.

9. The polymer filament of claim 1, wherein the polymer filament is capable of delivery through a catheter.

10. The polymer filament of claim 1, wherein the co-polymer is a co-polymer of a pentaerythritol ethoxylate and a polyethylene glycol.

11. The polymer filament of claim 1, wherein the co-polymer is a co-polymer of a pentaerythritol ethoxylate and a polyethylene glycol diacrylamide.